“Innoblative’s Sira RF ablation device offers unique capabilities that address shortcomings in the current advanced energy surgical market,” Londy said in prepared remarks. “I am thrilled to join this dynamic team and look forward to commercializing this next-generation RFA technology to improve the surgical experience for both physicians and patients.”
“We are delighted to welcome Kelly and her passion for innovation and patient-focused medical device solutions,” added co-founder & director Tyler Wanke. “Kelly brings a wealth of knowledge and experience in the MedTech market, specifically in diagnostic and therapeutic devices for cancer, making her an ideal fit to lead the company as we launch our commercial activities and additional clinical studies.”
Cala Health J&J venture exec Ryan for CEO
Medical wearables maker Cala Health last week said it named Renee Ryan as CEO, replacing founder Kate Rosenbluth, who’s slated to assume the chief scientific officer role.
As VP of venture investments at Johnson & Johnson Innovation, Ryan led that firm’s investment in Cala’s Series A round and 15 other investments.
“I have long admired Kate’s scientific prowess and am excited by the near-term potential of Cala Trio for essential tremor, as well as our bioelectronic non-invasive neuromodulation platform for multiple chronic diseases,” Ryan said in prepared remarks. “I’m thrilled and proud to see the swift trajectory of the company, including the recent $50 million Series C funding, and the phased launch of Cala Trio in the United States. I look forward to working with Kate and the talented team at Cala Health to maintain this momentum as we transition to a commercial organization.”
“I’m very pleased to partner with Renee to fuel the healthy growth and expansion of Cala Health,” Rosenbluth added. “Moreover, I’m excited to continue advancing our new products and realizing our vision to transform the standard of care for chronic disease with neuromodulation therapies.”
Den was an associate professor of radiation oncology at Thomas Jefferson University in Philadelphia.
“I envision alpha emitting radiation-based therapy being employed across multiple malignancies, either as primary therapy or in conjunction with immuno-oncology treatments. We have only scratched the surface of the potential indications for this technology. I am privileged to join the Alpha Tau team and take part in this exciting revolution in radiation oncology,” Den said in prepared remarks. “The prospects for Alpha DaRT are tremendous, and I look forward to helping clinicians around the world unleash its full potential.”
“I am glad to see leaders in their fields continuing to join Alpha Tau,” added CEO Uzi Sofer. “Having Dr. Den leading our medical team will be essential for our clinical efforts, especially as we approach the upcoming initiation of our clinical trials in the U.S. and Canada, and discussions with regulators on a potential marketing approval. Bobby brings a unique mix of medical and clinical expertise that will serve us well as we rapidly expand the base of practitioners providing this potentially life-saving treatment to patients in need.”
Orchestra BioMed promotes Cordis vet Donohoe to CMO
Orchestra BioMed last month appointed Dr. Dennis Donohoe, a longtime veteran of former Johnson & Johnson (NYSE:JNJ) subsidiary Cordis, as its full-time chief medical officer.
Donohoe was part-time CMO at Orchestra BioMed’s Focal Therapies group and its predecessor, Caliber Therapeutics, under a consulting agreement.
“I am excited to assume a full-time role as part of Orchestra BioMed’s leadership team during this critical growth period when I can help advance the development of Virtue SEB for coronary and peripheral artery disease as well as BackBeat CNT for targeted high blood pressure patient populations,” Donohoe said in prepared remarks. “As a physician, I was impressed by how these therapies have the potential to improve outcomes in areas of high unmet medical need while seamlessly integrating into existing clinical workflows within interventional cardiology and cardiac rhythm management. I truly believe that eventual regulatory approval and adoption of these technologies could have a lasting impact for patients, physicians and hospital systems worldwide.”
“Dennis Donohoe is a proven leader with extensive clinical and regulatory experience directly relevant to our therapeutic device product pipeline. We are thrilled that Dennis has agreed to join our management team on a full-time basis,” added chairman & CEO David Hochman. “We could not ask for a more qualified leader as we prepare to initiate a global clinical and regulatory development program focused on multiple coronary and peripheral indications for Virtue® SEB in collaboration with Terumo, our strategic partner. His extensive knowledge and expertise will also be vital to further our clinical and regulatory plans for BackBeat CNT for hypertension, our other flagship product, as well as additional pipeline development initiatives we expect to embark on in the future.”
MiMedx GC Haden scales back
MiMedx (NSDQ:MDXG) last month inked a consulting agreement with former general counsel & secretary Alexandra Haden for up to 40 hours a month through February 2020, at $8,000 per month plus nine months’ severance ($476,250).
- Obalon Therapeutics hires first medical director for retail clinic
- Ozop Surgical names ortho vet Ansari as sales & marketing EVP
- Shine Medical Technologies names Buurlage as European ops VP
- Podichetty out as Irras clinical affairs VP, Insanally in as regulatory affairs head, Asbury named project engineering head
- Donato tapped for chief business officer at Genetesis